Safety and Efficacy of Liraglutide in Combination With an OAD in Subjects With Type 2 Diabetes Insufficiently Controlled on OAD Alone
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 363 participants.
Also called NCT01512108
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 363 participants
- Sponsor
- Registry
-
NCT01512108
-
- Main results
- Liraglutide is effective and well tolerated in combination with an oral antidiabetic drug in Japanese patients with type 2 diabetes: A randomized, 52-week, open-label, parallel-group trial
- Other papers using this trial's data
- Safety and efficacy of the combination of the glucagon-like peptide-1 receptor agonist liraglutide with an oral antidiabetic drug in Japanese patients with type 2 diabetes: Post-hoc analysis of a randomized, 52-week, open-label, parallel-group trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT01512108. Randomized; no masking; primary purpose treatment. Start 2012-01-10 (actual); primary completion 2013-04-26 (actual). Results posted on 2014-05-28.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Efficacy of Liraglutide in Combination With an OAD in Subjects With Type 2 Diabetes Insufficiently Controlled on OAD Alone
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- liraglutide
- Intervention (Drug)
- oral anti-diabetic drug
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct01512108- Content hash
f671fad228b45cb86fd3c8512256c30ce6582c8100a0af827e39477399d59069